Phoenix, AZ Clinical Trials Report — June 2026

For patients and healthy volunteers in Phoenix, AZ, June 2026 presents a dynamic landscape of clinical trial opportunities. While new research initiatives are opening doors, some trials are rapidly approaching their enrollment deadlines, requiring prompt action from interested individuals.

Act Now: Trials Closing Soon in Phoenix

A total of 46 clinical trials in Phoenix are scheduled to close within the next 90 days. This urgency is particularly significant for healthy volunteers, as only 1 of these rapidly closing studies is still actively seeking participants without specific health conditions. This limited opportunity underscores the need for quick engagement.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder (3 trials)
• End stage liver disease (2 trials)
• Tricuspid regurgitation (2 trials)
• Amyotrophic lateral sclerosis (1 trial)
• Autism spectrum disorder (1 trial)
• Benign prostatic hyperplasia (BPH) (1 trial)
• Atrial fibrillation (AF) (1 trial)
• Burn wounds - partial thickness (2nd degree) (1 trial)
• Cervical spinal cord injury (1 trial)
• Chemotherapy induced neuropathic pain (1 trial)

New Research Opportunities Emerge

This month, Phoenix saw a significant increase in new clinical trials, with 17 new studies opening for enrollment. This is a notable rise from the 8 trials that launched in May 2026, indicating a growing research presence in the city. Overall, Phoenix currently has 843 clinical trials actively recruiting across 408 research facilities.

June brings several high-profile new trials to Phoenix, including significant Phase 3 studies from major pharmaceutical sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• AstraZeneca is sponsoring NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This Phase 3 study aims for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with Type 2 Diabetes Mellitus and increased cardiovascular risk.
• Also from Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," seeks 1,100 participants. This randomized, double-blind, placebo-controlled study will assess the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and Type 2 Diabetes Mellitus.
• BillionToOne Inc. is leading NCT07643896, "The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment." This study aims for 1,000 participants to compare a novel non-invasive circulating fetal cell assay to prenatal invasive diagnostic testing or postnatal genetic and clinical diagnoses.
• Mayo Clinic is sponsoring NCT07670117, "HAIQU (Hospital AIr QUality)," with 850 participants. The purpose of this research is to assess whether integrating an aerosol biosensor and air quality risk assessment software improves indoor air quality metrics in hospital environments and reduces risk factors associated with respiratory disease.
• The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is sponsoring NCT07637656, "Discovering Determinants of Food Intake by Application of Artificial Intelligence to Complex, High-Dimensional Data," seeking 800 participants. This study aims to understand factors related to food intake that can lead to weight gain over time.

New trials this month are exploring a range of conditions, with a particular focus on metabolic health. The most frequent conditions addressed are overweight (2 trials), chronic pain (2 trials), obesity (2 trials), and chronic weight management (2 trials). Drug trials account for the largest share of new studies, with 8 new drug trials, followed by 3 device trials.

Phoenix's Leading Research Facilities

Phoenix is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Phoenix Children's Hospital (62 trials)
• Cancer Center at Saint Joseph's (51 trials)
• Mayo Clinic Hospital in Arizona (49 trials)
• Mayo Clinic Arizona (37 trials)
• Research Site (36 trials)
• Phoenix Childrens Hospital (34 trials)
• Mayo Clinic (33 trials)
• Barrow Neurological Institute (25 trials)
• Mayo Clinic Hospital (19 trials)
• St. Joseph's Hospital and Medical Center (15 trials)
• Arizona State University (14 trials)
• Mayo Clinic in Arizona (11 trials)

These institutions offer a broad spectrum of research, from pediatric care at Phoenix Children's Hospital to oncology at the Cancer Center at Saint Joseph's, and diverse medical fields at the various Mayo Clinic locations and Barrow Neurological Institute.

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 17 new trials launched this month, 3 are actively seeking healthy volunteers. Across Phoenix, a total of 57 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, and 2 are female-only. Industry sponsors, including Eli Lilly and Company (2 trials), Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (2 trials), and AstraZeneca (2 trials), are driving a significant portion of these new research efforts.

Broadening Your Search: Nearby Options

While Phoenix offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Arizona. Cities with active trials include Chandler (6 trials), Tucson (6 trials), Tempe (3 trials), Peoria (3 trials), Scottsdale (3 trials), Sun City West (2 trials), Surprise (1 trial), and Mesa (1 trial).

As we move through June, Phoenix's growing research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.